# To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients

> **NCT01069926** · PHASE1 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 21 (actual)

## Conditions studied

- Glucose Lowering

## Interventions

- **DRUG:** AZD1656

## Key facts

- **NCT ID:** NCT01069926
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-03
- **Primary completion:** 2010-10
- **Final completion:** 2010-10
- **Target enrollment:** 21 (ACTUAL)
- **Last updated:** 2010-12-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01069926

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01069926, "To Assess the Pharmacokinetics of AZD1656 and Its Metabolite in Type 2 Diabetes Mellitus Patients". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01069926. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*